Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of LY3502970 in Chinese Participants With Obesity or Overweight
NCT06023095Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of orforglipron in obesity and Overweight (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration at Week 26. Started Sep 2023; status: completed.
02
Drugs
orforglipron
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06023095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06023095.